Checkpoint inhibitor approved in combination with chemotherapy in the first-line setting for these patients
News
Rinvoq scores positive results as a maintenance therapy for ulcerative colitis
JAK inhibitor hit primary endpoint of improved clinical remission at 52 weeks in maintenance study
Highest ever number of HCPs named on Disclosure UK, says ABPI
Data also shows pharma companies worked with fewer HCPS and HCOs in 2020 compared to 2019
JCVI recommends booster COVID-19 jabs for most vulnerable groups
Interim advice says boosters could be offered to priority groups from September
Gilead seeks US approval for long-acting HIV drug lenacapavir
Lenacapavir is designed to inhibit HIV-1 replication by interfering with a number of ‘essential’ steps in the viral lifecycle
MHRA approves Paion’s ‘ultra-short-acting’ anaesthetic Byfavo
The approval of Byfavo is based on data from a US-based Phase III clinical trial programme in procedural sedation
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer
Immunotherapy regimen approved to treat metastatic colorectal cancer after prior chemotherapy
bluebird bio’s sickle cell gene therapy granted MHRA ‘innovation passport’
Innovation passport designation scheme aims to reduce the time to market for promising treatments
Sanofi plans €400m annual investment in mRNA vaccines ‘centre of excellence’
Sanofi is currently collaborating with Translate Bio on a mRNA-based COVID-19 vaccine candidate
BioMarin resubmits haemophilia A gene therapy to the EMA
Company initially withdrew a marketing authorisation application for the gene therapy last year
ABPI launches updated Code of Practice
The new Code has been updated to reflect changes in the pharma environment
‘Mix and match’ COVID-19 vaccine study yields promising results
Mixing different vaccines produces a strong immune response against virus, according to researchers
CHMP recommends approval of UCB’s Bimzelx for plaque psoriasis
Bimzelx inhibits IL-17A and IL-17F, two key cytokines that drive inflammatory processes
Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial
All three doses of Lilly’s drug demonstrated superior HbA1C and body weight reductions compared to Ozempic
AZ doses first participants with COVID-19 variant vaccine
The vaccine has been designed with minor genetic alterations to the spike protein based on the beta (B.1.351) variant
